Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 202610 Citations
KPV3 residuesKPVEach bubble = one amino acid. Size = residue mass. Color = chemical class.KPV is a three-amino-acid fragment of alpha-MSH that suppresses NF-kB in inflamed gut tissue. It enters cells via the PepT1 transporter, preferentially targeting damaged intestinal epithelium. No human trials exist, but consistent community reports point to reduced bloating and colitis symptoms within 4 to 6 weeks.
200mcg · Daily
Summary: Add 2mL BAC water to your 5mg vial. Draw to 8.0 units on a U-100 syringe for a 200mcg dose. This vial will last 25 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 200mcg | Daily |
| Moderate | 500mcg | Daily |
| Aggressive | 1mg | Daily |
Start with the oral route if your goal is gut inflammation. The PepT1 transporter preferentially absorbs KPV in inflamed intestinal tissue, which is the whole point for IBD, IBS, and colitis. Reconstitution math for injectable: a 5 mg vial with 2 mL bacteriostatic water gives you 2,500 mcg/mL. For a 200 mcg dose, pull 8 units on a U-100 insulin syringe. For 500 mcg, pull 20 units. Oral dosing requires 2 to 3 times the subcutaneous dose. A 500 mcg oral dose delivers less active peptide to systemic circulation than 500 mcg subcutaneous. Account for GI degradation. Take oral KPV 30 minutes before food on an empty stomach. Dietary dipeptides compete at the PepT1 transporter, and eating too soon reduces uptake. The thing most beginners miss: this is not a fast-acting anti-inflammatory. KPV suppresses NF-kB upstream, not prostaglandin synthesis like NSAIDs. Expect 4 to 6 weeks for meaningful improvement. Running less than 4 weeks probably won't show you the full picture.
Dosing based on Very limited human data: dose based on preclinical and anecdotal reports — 12 published references.View all sources →
Cross-check your KPV reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
KPV is a three-amino-acid fragment of alpha-MSH that suppresses NF-kB in inflamed gut tissue. It enters cells via the PepT1 transporter, preferentially targeting damaged intestinal epithelium. No human trials exist, but consistent community reports point to reduced bloating and colitis symptoms within 4 to 6 weeks.
